# Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints

> **NCT03290287** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 26839 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Aclidinium bromide
- **DRUG:** Other COPD medication

## Key facts

- **NCT ID:** NCT03290287
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 26839 (ACTUAL)
- **Last updated:** 2023-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290287, "Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03290287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*